GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » Long-Term Debt

ANI Pharmaceuticals (FRA:BSFA) Long-Term Debt : €557.0 Mil (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ANI Pharmaceuticals Long-Term Debt?

ANI Pharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2024 was €557.0 Mil.

ANI Pharmaceuticals's quarterly Long-Term Debt increased from Mar. 2024 (€261.8 Mil) to Jun. 2024 (€264.2 Mil) and increased from Jun. 2024 (€264.2 Mil) to Sep. 2024 (€557.0 Mil).

ANI Pharmaceuticals's annual Long-Term Debt increased from Dec. 2021 (€253.6 Mil) to Dec. 2022 (€269.7 Mil) but then declined from Dec. 2022 (€269.7 Mil) to Dec. 2023 (€261.2 Mil).

ANI Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for ANI Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Long-Term Debt Chart

ANI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 158.23 141.75 253.57 269.67 261.18

ANI Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 267.08 261.18 261.84 264.20 557.01

ANI Pharmaceuticals  (FRA:BSFA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

ANI Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ANI Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » Long-Term Debt
Comparable Companies
HROW AVDL TLRY COLL PCRX PAHC KNSA IRWD EOLS ELTP ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
ANIP:USA
Address
210 Main Street West, Baudette, MN, USA, 56623
Website
https://www.anipharmaceuticals.com
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Headlines

No Headlines